NicOx Initiates New Trial To Establish HCT 3012 As Osteoarthritis Treatment With Beneficial Blood Pressure Profile

... NicOx S.A. (Eurolist: NICOX) today announced the initiation of a new clinical study designed to compare the 24-hour blood pressure profile of HCT 3012 and naproxen, using ambulatory blood pressure monitoring (ABPM). This study is expected to enroll approximately 120 volunteer subjects with stable essential hypertension (high blood pressure) at 15 clinical centers in the United States... click link for more info. ...